Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018’, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis)

- The report reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Vaginal Atrophy (Atrophic Vaginitis) therapeutics and enlists all their major and minor projects

- The report assesses Vaginal Atrophy (Atrophic Vaginitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ligand Pharmaceuticals Inc

Medinova AG

Mithra Pharmaceuticals SA

TherapeuticsMD Inc

Ligand Pharmaceuticals Inc

Medinova AG

Mithra Pharmaceuticals SA

TherapeuticsMD Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vaginal Atrophy (Atrophic Vaginitis) – Overview

Vaginal Atrophy (Atrophic Vaginitis) ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vaginal Atrophy (Atrophic Vaginitis) – Overview

Vaginal Atrophy (Atrophic Vaginitis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vaginal Atrophy (Atrophic Vaginitis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vaginal Atrophy (Atrophic Vaginitis) – Companies Involved in Therapeutics Development

Ligand Pharmaceuticals Inc

Medinova AG

Mithra Pharmaceuticals SA

TherapeuticsMD Inc

Vaginal Atrophy (Atrophic Vaginitis) – Drug Profiles

(estriol + lactobacillus) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estetrol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lasofoxifene tartrate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-006HR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-008HR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaginal Atrophy (Atrophic Vaginitis) – Dormant Projects

Vaginal Atrophy (Atrophic Vaginitis) – Product Development Milestones

Featured News & Press Releases

May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor

Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting

Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2018

Number of Products under Development by Companies, H1 2018

Products ...

List of Tables

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) – Pipeline by Ligand Pharmaceuticals Inc, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) – Pipeline by Medinova AG, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) – Pipeline by Mithra Pharmaceuticals SA, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) – Pipeline by TherapeuticsMD Inc, H1 2018

Vaginal Atrophy (Atrophic Vaginitis) – Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Figures

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports